Prolonged benefit in the treatment of chronic idiopathic urticaria with astemizole.

Abstract

A double-blind clinical trial of 51 patients with chronic idiopathic urticaria using oral astemizole for 8 weeks demonstrated significant improvement in symptoms and lesions in 75% of treated patients versus 20% in the placebo group. The suppression of urticaria persisted for an average of 38 days, demonstrating the long duration of action of astemizole.

• Authors: R W Honsinger Jr, R J Thomsen
• Journal: Annals of allergy (Ann Allergy) Vol. 65 Issue 3 Pg. 194-200 (Sep 1990) ISSN: 0003-4738 [Print] United States
• PMID: 1976298 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Benzimidazoles
• Histamine H1 Antagonists
• Astemizole

Topics

• Astemizole
• Benzimidazoles (adverse effects, therapeutic use)
• Chronic Disease
• Clinical Trials as Topic
• Double-Blind Method
• Histamine H1 Antagonists (therapeutic use)
• Humans
• Time Factors
• Urticaria (drug therapy, pathology)